The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Activity of DEM301, a novel anti-DEM-TXX antibody-drug conjugate for the treatment of gastrointestinal tumors.
 
Sarah Carden
Employment - DEM Biopharma
Stock and Other Ownership Interests - DEM Biopharma; Sonata Therapeutics
Research Funding - DEM Biopharma
Patents, Royalties, Other Intellectual Property - As part of work at DEM Biopharma am on patents related to that work (Inst)
Travel, Accommodations, Expenses - DEM Biopharma
 
Agnieszka Denslow
Employment - DEM BioPharma
Stock and Other Ownership Interests - DEM BioPharma
 
Carmen Adriaens
Employment - DEM BioPharma; SQZ Biotechnology
 
Peter Sandy
Employment - DEM BioPharma
Stock and Other Ownership Interests - DEM BioPharma
Consulting or Advisory Role - StingThera
 
Sandeep Kumar
No Relationships to Disclose
 
Loise Francisco
Employment - DEM Biopharma
Leadership - DEM Biopharma; Simcere (I)
Stock and Other Ownership Interests - DEM Biopharma; GlaxoSmithKline; Lilly (I); Merck; Moderna Therapeutics; Novartis
Consulting or Advisory Role - Simcere (I)
Research Funding - DEM Biopharma
Patents, Royalties, Other Intellectual Property - Author on DEM Biopharma patents filed on work presented in this abstract; Patents from work at Harvard Medical School on PD-1 pathway.
Travel, Accommodations, Expenses - DEM Biopharma; Simcere (I)